{"id":"W3087416729","doi":"10.1056/nejmoa2022485","title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":766,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Daiichi Sankyo Europe; Pharmacyclics; Merck Sharp and Dohme; EMD Serono; Genentech; Foundation Medicine; Sierra Oncology; Bavarian Nordic; Astellas Pharma; Eisai; Celldex Therapeutics; Daiichi-Sankyo; Clovis Oncology; National Institute for Health and Care Research; AstraZeneca; Invitae; Ipsen; Vertex Pharmaceuticals; Boston Scientific Corporation; Endocyte; NRG Oncology; F. Hoffmann-La Roche; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Prostate cancer; Oncology; Medicine; Internal medicine; Cancer research; Cancer; Biology; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006487305,0.0001898093,0.0003331352,0.0002814861,0.0002044186,0.0002674017,0.000136915,0.0001545217,0.0006245902],"category_scores_gemma":[0.001295368,0.000060063,0.0003544636,0.0003485682,0.0001616503,0.0001752153,0.0002813028,0.0004051974,0.00006229001],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004084718,"about_ca_system_score_gemma":0.0003579064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007593753,"about_ca_topic_score_gemma":0.001338522,"domain_scores_codex":[0.9997589,0.00008719559,0.00001476406,0.00005058902,0.00004573625,0.00004273369],"domain_scores_gemma":[0.9992004,0.0002439091,0.0002951655,0.00003799683,0.00004243131,0.0001801255],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04230272,0.000942716,0.7750239,0.0004630481,0.0007787969,0.001084709,0.0003692289,0.005392761,0.01357155,0.0002567416,0.002079303,0.1577345],"study_design_scores_gemma":[0.001642202,0.01720573,0.9675869,0.00008012661,0.0003988429,0.002710314,0.000122903,0.003047091,0.002839848,0.0006494153,0.003687884,0.00002863964],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970098,0.002161989,0.0001467807,0.00006756232,0.00000936422,0.000009829138,0.000159801,0.000006855905,0.0004279526],"genre_scores_gemma":[0.999262,0.0003860841,0.00006173123,0.00002873275,0.00001528206,0.000007705479,0.0001854373,0.000001112761,0.00005195595],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007593753,"threshold_uncertainty_score":0.003430903,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06052038105550388,"score_gpt":0.343200598017492,"score_spread":0.2826802169619881,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}